Phase 2 Multi-Center Study Of Tazemetostat (Epz-6438), An Inhibitor Of Enhancer Of Zeste-Homolog 2 (Ezh2), In Patients With Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma (Nhl).
JOURNAL OF CLINICAL ONCOLOGY（2016）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要